{"id":1153,"date":"2020-09-02T09:54:08","date_gmt":"2020-09-02T07:54:08","guid":{"rendered":"http:\/\/haavind.local\/en\/2020\/09\/02\/pharma-report-summer-2020\/"},"modified":"2025-08-29T07:08:44","modified_gmt":"2025-08-29T07:08:44","slug":"pharma-report-summer-2020","status":"publish","type":"post","link":"https:\/\/haavind.no\/en\/pharma-report-summer-2020\/","title":{"rendered":"The Haavind Pharma Report Summer 2020"},"content":{"rendered":"\t<div class=\"template-post alignwide wp-block-dekode-hero\">\n\t\t<div class=\"hero__inner\">\n\t\t\t<div class=\"hero__inner_blocks\">\n\t\t\t\t\n<h1 class=\"wp-block-post-title\">The Haavind Pharma Report Summer 2020<\/h1>\n\n\n<p>Haavind\u2019s Pharma Report is a retrospective report on legal developments in Norway relevant for the pharmaceutical sector and focuses on relevant developments within regulatory affairs and intellectual property. Since 2016, we have published the report twice a year, and we are pleased once again to present some of the significant legal developments that occurred during the first half of 2020.<\/p>\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div><\/div>\n\t\t\t\t\t<div class=\"post-meta\">\n\t\t\t\t\t\t<span class=\"info-small\">02 September, 2020 \u00b7 2 min. reading time<\/span>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\n\n<div class=\"alignleft wp-block-haavind-byline\">\n\t\t\t\t<span class=\"author-tag\">Contact person<\/span>\n\t\t\t\t<div class=\"authors\"><a href=\"https:\/\/haavind.no\/en\/people\/hakon-austdal\/\" class=\"t2-byline__author-link\">\n\t\t\t\t<div class=\"author-inner\">\n\t\t\t\t\t<div class=\"author-inner__image\"><img loading=\"lazy\" decoding=\"async\" width=\"233\" height=\"300\" src=\"https:\/\/haavind.no\/content\/uploads\/sites\/2\/2016\/04\/Ha\u030akon-Austdal-233x300.jpg\" class=\"attachment-medium size-medium wp-post-image\" alt=\"\" srcset=\"https:\/\/haavind.no\/content\/uploads\/sites\/2\/2016\/04\/Ha\u030akon-Austdal-233x300.jpg 233w, https:\/\/haavind.no\/content\/uploads\/sites\/2\/2016\/04\/Ha\u030akon-Austdal-768x989.jpg 768w, https:\/\/haavind.no\/content\/uploads\/sites\/2\/2016\/04\/Ha\u030akon-Austdal-795x1024.jpg 795w, https:\/\/haavind.no\/content\/uploads\/sites\/2\/2016\/04\/Ha\u030akon-Austdal.jpg 800w\" sizes=\"(max-width: 233px) 100vw, 233px\" \/><\/div>\n\t\t\t\t\t<div>\n\t\t\t\t\t\t<span class=\"name\">H\u00e5kon Austdal<\/span>\n\t\t\t\t\t\t<span>Specialist Counsel<\/span>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/a><\/div>\n\t\t\t\t<div class=\"topics\">\n\t\t\t\t<span>Topics<\/span>\n\t\t\t\t<div><a class=\"tag-link\" href=\"https:\/\/haavind.no\/en\/kompetanse\/bransje\/healthcare-and-life-science\/\">Healthcare and life science<\/a><\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n<p>Haavind\u2019s Pharma Report is a retrospective report on legal developments in Norway relevant for the pharmaceutical sector and focuses on relevant developments within regulatory affairs and intellectual property. Since 2016, we have published the report twice a year, and we are pleased once again to present some of the significant legal developments that occurred during the first half of 2020.<\/p>\n\n\n\n<p>In the Summer 2020 edition, we take a closer look on the Norwegian government\u2019s proposal to allow pharmacies to substitute biological medicinal products. The report also takes a closer look at the new rules on advertising of medicinal products which recently entered into force, as well as many other interesting developments.<\/p>\n\n\n\n<p>Earlier this year, Haavind also arranged a breakfast seminar on the opportunities and challenges in commercialization of Big Data for the healthcare sector, which we held in collaboration with the Danish data analyst and service provider <a href=\"https:\/\/dlimi.com\/\">DLIMI<\/a>. A brief summary of the seminar is available in the report.<a href=\"https:\/\/haavind.no\/content\/uploads\/sites\/2\/2020\/09\/Pharma-Summer-Report-2020_Web.pdf\">Download the Pharma Report Summer 2020 here<\/a><\/p>\n\n\n\t<div \n\t\tclass=\"template-post alignwide wp-block-haavind-block-contact-people\" id=\"contact\"\t\t>\n\t\t<h2 class=\"post-featured-title\">Contact us<\/h2>\n\t\t<div class=\"block-contact-people-list\">\n\t\t\t\n<div class=\"t2-featured-content-layout alignwide wp-block-t2-featured-content-layout\">\n<div class=\"t2-featured-single-post t2-featured-content is-post-type-person sector-fisheries-and-aquaculture sector-healthcare-and-life-science sector-technology sector-retail speciality-food speciality-intellectual-property-rights role-specialist-counsel wp-block-t2-featured-single-post\">\n<div class=\"wp-block-group alignfull post-featured-image is-layout-flow wp-block-group-is-layout-flow\">\n\t<a class=\"t2-post-link wp-block-t2-post-link\" href=\"https:\/\/haavind.no\/en\/people\/hakon-austdal\/\">\n\t<figure style=\"--t2-focal-point: 50% 50%\" class=\"t2-post-featured-image has-image-ratio-3-4 wp-block-t2-post-featured-image\"><img loading=\"lazy\" decoding=\"async\" width=\"795\" height=\"1024\" src=\"https:\/\/haavind.no\/content\/uploads\/sites\/2\/2016\/04\/Ha\u030akon-Austdal-795x1024.jpg\" class=\"attachment-large size-large wp-post-image\" alt=\"\" \/><\/figure>\n\t<\/a>\n<\/div>\n\n\n<div class=\"wp-block-group alignfull post-featured-content is-layout-flow wp-block-group-is-layout-flow\">\n\t<a class=\"t2-post-link wp-block-t2-post-link\" href=\"https:\/\/haavind.no\/en\/people\/hakon-austdal\/\"><h2 class=\"t2-post-title wp-block-t2-post-title\">H\u00e5kon Austdal<\/h2><\/a>\n\t<div class=\"taxonomy-role wp-block-post-terms\"><a href=\"https:\/\/haavind.no\/en\/role\/specialist-counsel\/\" rel=\"tag\">Specialist Counsel<\/a><\/div>\n\t<div class=\"card-info wp-block-t2-people-meta\"><div class=\"card-info__post-meta meta-key-people_email\"><a href=\"mailto:h.austdal@haavind.no\">h.austdal@haavind.no<\/a><\/div><div class=\"card-info__post-meta meta-key-people_phone\"><a href=\"tel:+47 920 19 526\">+47 920 19 526<\/a><\/div><\/div>\n<\/div>\n\n<\/div>\n<\/div>\n\t\t<\/div>\n\t\t\t<\/div>\n\t\n\n\n<figure class=\"wp-block-image alignleft\"><img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"624\" src=\"https:\/\/haavind.no\/content\/uploads\/sites\/2\/2022\/06\/LinkedIn_Pharma-Report.jpg\" alt=\"\" class=\"wp-image-1912\" title=\"LinkedIn_Pharma Report\" srcset=\"https:\/\/haavind.no\/content\/uploads\/sites\/2\/2022\/06\/LinkedIn_Pharma-Report.jpg 1200w, https:\/\/haavind.no\/content\/uploads\/sites\/2\/2022\/06\/LinkedIn_Pharma-Report-300x156.jpg 300w, https:\/\/haavind.no\/content\/uploads\/sites\/2\/2022\/06\/LinkedIn_Pharma-Report-1024x532.jpg 1024w, https:\/\/haavind.no\/content\/uploads\/sites\/2\/2022\/06\/LinkedIn_Pharma-Report-768x399.jpg 768w\" sizes=\"(max-width: 1200px) 100vw, 1200px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Haavind\u2019s Pharma Report is a retrospective report on legal developments in Norway relevant for the pharmaceutical sector and focuses on relevant developments within regulatory affairs and intellectual property. Since 2016, we have published the report twice a year, and we are pleased once again to present some of the significant legal developments that occurred during the first half of 2020.<\/p>\n","protected":false},"author":57,"featured_media":1912,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"sector":[7],"speciality":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.2 (Yoast SEO v24.2) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The Haavind Pharma Report Summer 2020 - Haavind EN<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/haavind.no\/en\/pharma-report-summer-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Haavind Pharma Report Summer 2020\" \/>\n<meta property=\"og:description\" content=\"Haavind\u2019s Pharma Report is a retrospective report on legal developments in Norway relevant for the pharmaceutical sector and focuses on relevant developments within regulatory affairs and intellectual property. Since 2016, we have published the report twice a year, and we are pleased once again to present some of the significant legal developments that occurred during the first half of 2020.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/haavind.no\/en\/pharma-report-summer-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Haavind EN\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-02T07:54:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-29T07:08:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/haavind.no\/content\/uploads\/sites\/2\/2022\/06\/LinkedIn_Pharma-Report.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"624\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Camilla\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Camilla\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/haavind.no\/en\/pharma-report-summer-2020\/\",\"url\":\"https:\/\/haavind.no\/en\/pharma-report-summer-2020\/\",\"name\":\"The Haavind Pharma Report Summer 2020 - Haavind EN\",\"isPartOf\":{\"@id\":\"https:\/\/haavind.no\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/haavind.no\/en\/pharma-report-summer-2020\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/haavind.no\/en\/pharma-report-summer-2020\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/haavind.no\/content\/uploads\/sites\/2\/2022\/06\/LinkedIn_Pharma-Report.jpg\",\"datePublished\":\"2020-09-02T07:54:08+00:00\",\"dateModified\":\"2025-08-29T07:08:44+00:00\",\"author\":{\"@id\":\"https:\/\/haavind.no\/en\/#\/schema\/person\/0701bc9d64854d65dd3e774b33118f6d\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/haavind.no\/en\/pharma-report-summer-2020\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/haavind.no\/en\/pharma-report-summer-2020\/#primaryimage\",\"url\":\"https:\/\/haavind.no\/content\/uploads\/sites\/2\/2022\/06\/LinkedIn_Pharma-Report.jpg\",\"contentUrl\":\"https:\/\/haavind.no\/content\/uploads\/sites\/2\/2022\/06\/LinkedIn_Pharma-Report.jpg\",\"width\":1200,\"height\":624},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/haavind.no\/en\/#website\",\"url\":\"https:\/\/haavind.no\/en\/\",\"name\":\"Haavind EN\",\"description\":\"-\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/haavind.no\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/haavind.no\/en\/#\/schema\/person\/0701bc9d64854d65dd3e774b33118f6d\",\"name\":\"Camilla\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/haavind.no\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/056dd7829c9994cb22af97c497641075?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/056dd7829c9994cb22af97c497641075?s=96&d=mm&r=g\",\"caption\":\"Camilla\"},\"url\":\"https:\/\/haavind.no\/en\/author\/camilla\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The Haavind Pharma Report Summer 2020 - Haavind EN","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/haavind.no\/en\/pharma-report-summer-2020\/","og_locale":"en_US","og_type":"article","og_title":"The Haavind Pharma Report Summer 2020","og_description":"Haavind\u2019s Pharma Report is a retrospective report on legal developments in Norway relevant for the pharmaceutical sector and focuses on relevant developments within regulatory affairs and intellectual property. Since 2016, we have published the report twice a year, and we are pleased once again to present some of the significant legal developments that occurred during the first half of 2020.","og_url":"https:\/\/haavind.no\/en\/pharma-report-summer-2020\/","og_site_name":"Haavind EN","article_published_time":"2020-09-02T07:54:08+00:00","article_modified_time":"2025-08-29T07:08:44+00:00","og_image":[{"width":1200,"height":624,"url":"https:\/\/haavind.no\/content\/uploads\/sites\/2\/2022\/06\/LinkedIn_Pharma-Report.jpg","type":"image\/jpeg"}],"author":"Camilla","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Camilla","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/haavind.no\/en\/pharma-report-summer-2020\/","url":"https:\/\/haavind.no\/en\/pharma-report-summer-2020\/","name":"The Haavind Pharma Report Summer 2020 - Haavind EN","isPartOf":{"@id":"https:\/\/haavind.no\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/haavind.no\/en\/pharma-report-summer-2020\/#primaryimage"},"image":{"@id":"https:\/\/haavind.no\/en\/pharma-report-summer-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/haavind.no\/content\/uploads\/sites\/2\/2022\/06\/LinkedIn_Pharma-Report.jpg","datePublished":"2020-09-02T07:54:08+00:00","dateModified":"2025-08-29T07:08:44+00:00","author":{"@id":"https:\/\/haavind.no\/en\/#\/schema\/person\/0701bc9d64854d65dd3e774b33118f6d"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/haavind.no\/en\/pharma-report-summer-2020\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/haavind.no\/en\/pharma-report-summer-2020\/#primaryimage","url":"https:\/\/haavind.no\/content\/uploads\/sites\/2\/2022\/06\/LinkedIn_Pharma-Report.jpg","contentUrl":"https:\/\/haavind.no\/content\/uploads\/sites\/2\/2022\/06\/LinkedIn_Pharma-Report.jpg","width":1200,"height":624},{"@type":"WebSite","@id":"https:\/\/haavind.no\/en\/#website","url":"https:\/\/haavind.no\/en\/","name":"Haavind EN","description":"-","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/haavind.no\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/haavind.no\/en\/#\/schema\/person\/0701bc9d64854d65dd3e774b33118f6d","name":"Camilla","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/haavind.no\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/056dd7829c9994cb22af97c497641075?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/056dd7829c9994cb22af97c497641075?s=96&d=mm&r=g","caption":"Camilla"},"url":"https:\/\/haavind.no\/en\/author\/camilla\/"}]}},"_links":{"self":[{"href":"https:\/\/haavind.no\/en\/wp-json\/wp\/v2\/posts\/1153"}],"collection":[{"href":"https:\/\/haavind.no\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haavind.no\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haavind.no\/en\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/haavind.no\/en\/wp-json\/wp\/v2\/comments?post=1153"}],"version-history":[{"count":2,"href":"https:\/\/haavind.no\/en\/wp-json\/wp\/v2\/posts\/1153\/revisions"}],"predecessor-version":[{"id":7166,"href":"https:\/\/haavind.no\/en\/wp-json\/wp\/v2\/posts\/1153\/revisions\/7166"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haavind.no\/en\/wp-json\/wp\/v2\/media\/1912"}],"wp:attachment":[{"href":"https:\/\/haavind.no\/en\/wp-json\/wp\/v2\/media?parent=1153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haavind.no\/en\/wp-json\/wp\/v2\/categories?post=1153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haavind.no\/en\/wp-json\/wp\/v2\/tags?post=1153"},{"taxonomy":"sector","embeddable":true,"href":"https:\/\/haavind.no\/en\/wp-json\/wp\/v2\/sector?post=1153"},{"taxonomy":"speciality","embeddable":true,"href":"https:\/\/haavind.no\/en\/wp-json\/wp\/v2\/speciality?post=1153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}